Secondly, our findings warrant caution in the directly injection of TLR9 agonist CpG ODN into glioma tissues for the glioma immunotherapy., this conclusion may be contradictory to some researcher's work[13,41,42]. This evidence concerns the gene TLR9 and glioma.